Back HCV Prevention

EASL 2015: Reinfection after HCV Cure - Long-term Support Needed for People Who Have Injected Drugs

Reinfection rates after a hepatitis C cure among people who inject drugs, as well as past drug users, are relatively low, according to findings from studies from Norway and Canada presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress in Vienna in April. The findings suggest that current and former injection drug users who have been cured of hepatitis C require ongoing support to remain free of HCV, but also indicate that fears of a high rate of reinfection should not be used as a reason to withhold hepatitis C treatment from people who inject drugs.

alt

Read more:

EASL 2015: Civacir Immune Globulin May Help Prevent HCV Reinfection after Liver Transplant

Civacir, a hepatitis C immune globulin or antibody product, reduced the likelihood of hepatitis C virus infecting the new liver graft after transplantation in patients who were receiving but had not yet completed antiviral treatment, according to preliminary study findings presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.

alt

Read more:

Clinicians Report 2 Acute HCV Infections in Kaiser PrEP Program

Two HIV negative men gay receiving HIV pre-exposure prophylaxis (PrEP) through Kaiser Permanente in San Francisco were newly infected with hepatitis C virus (HCV), with sex being their only apparent risk factor, Kaiser clinicians reported in the February 18 issue of Clinical Infectious Diseases.

alt

Read more:

CROI 2015: HCV Sexual Transmission Linked to Anal Sex, Drug Use, Lower CD4 Count

In addition to the usual risk factors for hepatitis C virus (HCV) sexual transmission seen in most previous studies -- such as anal sex and having other sexually transmitted infections -- researchers in the Netherlands also saw an association with nasal and injection drug use and lower CD4 T-cell count, they reported in a poster presentation at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

Read more:

Hepatitis C Vaccine Is Safe and Induces Immune Responses in Early Human Trial

A new hepatitis C vaccine demonstrated good safely and tolerability in a first-in-humans Phase 1 clinical trial, with only mild and transient side effects, according to a report in the November 5 edition of Science Translational Medicine. The vaccine, which mimics immune responses in people who naturally clear hepatitis C virus (HCV) infection, led to increased production of T-cells targeting the virus. Phase 2 studies are now underway in Baltimore and San Francisco, with results expected in 2016.

alt

Read more: